Trial Profile
The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms QUATRO
- 14 Jul 2014 New trial record